Huashen Technology

Chengdu Huashen Technology Group is a prominent Chinese biopharmaceutical company that integrates modern biotechnology with Traditional Chinese Medicine (TCM). The company's flagship product, Licartin (Iodine[131I] Metuximab Injection), is a pioneering radioimmunotherapy targeting CD147 for the treatment of primary liver cancer. Huashen also maintains a strong presence in the cardiovascular and cerebrovascular markets with its Sanqi Tongshu Capsule, a standardized TCM product. Headquartered in Chengdu, the company operates multiple GMP-certified manufacturing facilities and maintains a robust R&D pipeline focused on oncology and chronic disease management. Huashen is publicly traded on the Shenzhen Stock Exchange and continues to expand its footprint in the global life sciences sector through strategic innovation.